GlassScriptPhysician profile
Calvin Bradley
NPI 1780096578
$1,783.69
in general payments reported to CMS, 2019-2025
22 companies · $934 in 2025
The $934 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.08 · 2023: $34.31 · 2024: $764 · 2025: $934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,731.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $557.06 | 2024-2025 | |
| Lilly USA, LLC | $301.47 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $238.18 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $74.49 | 2024-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.30 | 2024-2025 | Xifaxan |
| Novo Nordisk INC | $62.16 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $61.95 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Corium, LLC | $57.64 | 2024-2025 | Azstarys |
| Kowa Pharmaceuticals America, INC. | $53.78 | 2024-2025 | Zoryve |
| Sumitomo Pharma America, INC. | $42.02 | 2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.31 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $36.38 | 2023-2024 | Trelegy Ellipta |
| Pfizer INC. | $36.09 | 2024-2025 | |
| Allergan, INC. | $35.68 | 2019 | |
| Exact Sciences Corporation | $19.71 | 2025 | The Cologuard Plus Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $16.21 | 2025 | Trintellix |
| Dexcom, INC. | $15.77 | 2024 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $14.84 | 2025 | |
| Amgen INC. | $14.48 | 2024 | Repatha, Otezla |
| Phathom Pharmaceuticals, INC. | $13.90 | 2024 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $13.37 | 2024 | Eliquis |
| Dynavax Technologies Corporation | $11.90 | 2025 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Calvin Bradley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.